Li L, Wang Z, Cui L, et al.

Title: Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Citation: Clin Transl Allergy
2021;11:e12038.

Country: USA | Indication: Asthma

This is an independent study

http://tago.ca/34123366
Scan to access the publication or visit
http://tago.ca/34123366